(Q37161925)

18 August 2017

1 reference

title

Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents (English)

1 reference

18 August 2017

0 references

Pitocco D

1

1 reference

18 August 2017

Valle D

series ordinal

2

1 reference

18 August 2017

Rossi A

series ordinal

3

1 reference

18 August 2017

Gentilella R

series ordinal

4

1 reference

18 August 2017

1 April 2008

1 reference

Journal of Endocrinological Investigation

18 August 2017

1 reference

18 August 2017

31

1 reference

18 August 2017

4

1 reference

18 August 2017

371-379

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03346373

18 August 2017

0 references

cites work

Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Deteriorating beta-cell function in type 2 diabetes: a long-term model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Sulfonylurea induced beta-cell apoptosis in cultured human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Standards of medical care in diabetes--2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Rationale for the association of sulfonylurea and insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Secondary sulphonylurea failure: what pathogenesis is responsible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

The beta cell function in NIDDM patients with secondary failure: a three year follow-up of combined oral hypoglycemic and insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Short-term intensive insulin therapy in newly diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Glucagon-like peptide-1 prevents beta cell glucolipotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Glycosylated Hemoglobin: Finally Ready for Prime Time as a Cardiovascular Risk Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346373

Twice daily insulin therapy in patients with type 2 diabetes and secondary failure to sulphonylureas.

21 January 2018

1 reference

12 December 2020

The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management--2000 update

1 reference

12 December 2020

Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes

1 reference

12 December 2020

[Combination therapy with sulfonylurea plus insulin in "secondary failure" of type 2 diabetes]

1 reference

12 December 2020

Morning or bedtime NPH insulin combined with sulfonylurea in treatment of NIDDM

1 reference

12 December 2020

Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure.

1 reference

12 December 2020

[The utility of postprandial C-peptide evaluation in type 2 diabetes]

1 reference

12 December 2020

Sex differences in the coronary heart disease risk profile: a possible role for insulin. The Beaver County Study.

1 reference

12 December 2020

Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe)

1 reference

12 December 2020

When oral agents fail: practical barriers to starting insulin

1 reference

12 December 2020

In search of normoglycaemia in diabetes: controlling postprandial glucose

1 reference

12 December 2020

Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic beta-cells.

1 reference

12 December 2020

Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up

1 reference

12 December 2020

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

[Commentary to the article: Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43]

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03346373

1 reference

18 August 2017

1 reference